The CD40/CD40 ligand (CD40L) costimulatory system, which amplifies immune responses and can induce inflammation, is believed to have a role in skin manifestations of other autoimmune diseases ...

UCB and Biogen’s drug dapirolizumab pegol has met the primary endpoint of improvement in disease activity in lupus patients.

这些药物包括：优化肿瘤抗原释放和呈递的药物（放疗，化疗，癌症疫苗，溶瘤病毒），激活共刺激分子以改善抗原呈递细胞（APCs）活性（靶向ICOS，ICOSL，OX40，CD40和CD40L的受体激动剂），以及靶向先天免疫的药物，例如：模式识别受体（PRRs）、细胞因子、自然 ...

Frexalimab is described by Sanofi as a ‘second-generation’ anti-CD40L antibody that can block the costimulatory CD40/CD40L cellular pathway necessary for adaptive and immune cell activation ...

One such molecule is the CD40L, which engages CD40 on dendritic and B cells of the immune system, enabling T cells to become activated as a result. Rodent studies using coreceptor blockade with ...

CD40–CD40L signaling may regulate both the initiation and effector phases of B- and T-cell responses, as well as transmigration of activated cells to target tissues. Direct therapy against this ...

The firm’s compound in development is AT-1501, a humanized IgG1 anti-CD40L antibody with high affinity for CD40 ligand (CD40L, also called CD154), a well-validated biological target with broad ...

An example of this is dazodalibep (HZN-4920), a next-generation fusion protein designed to block CD40 ligand (CD40L), which, through its interaction with CD40, plays a crucial role in activating B ...

Tonix Pharmaceuticals (NASDAQ: TNXP) , a fully integrated biopharmaceutical company with marketed products and a pipeline of development candidates ...

Thomas brings more than 20 years of commercial and operations experience in the biopharmaceutical industry to Tonix Tonix is ...